Sviss - þýska - Swissmedic (Swiss Agency for Therapeutic Products)

amgen switzerland ag - darbepoetinum alfa - injektionslösung in fertigspritze - darbepoetinum alfa 150 µg, natrii dihydrogenophosphas monohydricus, dinatrii phosphas, natrii chloridum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 0.3 ml corresp., natrium 1.14 mg. - stimulierung der erythropoese - biotechnologika

Sviss - þýska - Swissmedic (Swiss Agency for Therapeutic Products)

amgen switzerland ag - darbepoetinum alfa - injektionslösung in fertigspritze - darbepoetinum alfa 300 µg, natrii dihydrogenophosphas monohydricus, dinatrii phosphas, natrii chloridum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 0.6 ml corresp., natrium 2.27 mg. - stimulierung der erythropoese - biotechnologika

Sviss - þýska - Swissmedic (Swiss Agency for Therapeutic Products)

amgen switzerland ag - darbepoetinum alfa - injektionslösung in fertigspritze - darbepoetinum alfa 500 µg, natrii dihydrogenophosphas monohydricus, dinatrii phosphas, natrii chloridum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 1 ml, natrium 3.79 mg. - stimulierung der erythropoese - biotechnologika

Sviss - þýska - Swissmedic (Swiss Agency for Therapeutic Products)

amgen switzerland ag - darbepoetinum alfa - injektionslösung in fertigspritze - darbepoetinum alfa 130 µg, natrii phosphates, natrii chloridum, polysorbatum 80, aqua ad iniectabilia q.s. ad solutionem pro 0.65 ml corresp., darbepoetinum alfa 200 µg/ml. - stimulierung der erythropoese - biotechnologika

Sviss - þýska - Swissmedic (Swiss Agency for Therapeutic Products)

amgen switzerland ag - pegfilgrastimum - injektionslösung in einer fertigspritze - pegfilgrastimum 6 mg, acidum aceticum glaciale, natrii hydroxidum corresp. natrium 20.4 µg, sorbitolum 30 mg, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 0.6 ml. - neutropenie - biotechnologika

Sviss - þýska - Swissmedic (Swiss Agency for Therapeutic Products)

amgen switzerland ag - cinacalcetum - filmtabletten - cinacalcetum 30 mg zu cinacalceti hydrochloridum, für amylum pregelificatum, cellulosum microcristallinum, povidonum k 29-32, crospovidonum, silica colloidalis anhydrica, magnesium stearas, Überzug: lactosum monohydricum 2.88 mg, hypromellosum, e 171, triacetinum, e 132, e 172, macrogolum 400, carnauba-wachs, für compresso dunst. - hyperparathyreoidismus - synthetika

Sviss - þýska - Swissmedic (Swiss Agency for Therapeutic Products)

amgen switzerland ag - cinacalcetum - filmtabletten - cinacalcetum 60 mg zu cinacalceti hydrochloridum, für amylum pregelificatum, cellulosum microcristallinum, povidonum k 29-32, crospovidonum, silica colloidalis anhydrica, magnesium stearas, Überzug: lactosum monohydricum 5.76 mg, hypromellosum, e 171, triacetinum, e 132, e 172, macrogolum 400, carnauba-wachs, für compresso dunst. - hyperparathyreoidismus - synthetika

Sviss - þýska - Swissmedic (Swiss Agency for Therapeutic Products)

amgen switzerland ag - cinacalcetum - filmtabletten - cinacalcetum 90 mg bis cinacalceti hydrochloridum, für amylum pregelificatum, cellulosum microcristallinum, povidonum k 29-32, crospovidonum, silica colloidalis anhydrica, magnesium stearas, Überzug: lactosum monohydricum 8.64 mg, hypromellosum, e 171, triacetinum, e 132, e 172, macrogolum 400, carnauba-wachs, für compresso dunst. - hyperparathyreoidismus - synthetika

Sviss - þýska - Swissmedic (Swiss Agency for Therapeutic Products)

amgen switzerland ag - darbepoetinum alfa - injektionslösung in vorgefülltem pen (sureclick) - darbepoetinum alfa 10 µg, natrii phosphates, natrii chloridum, polysorbatum 80, aqua ad iniectabilia q.s. ad solutionem pro 0.4 ml corresp., darbepoetinum alfa 25 µg/ml. - stimulierung der erythropoese - biotechnologika

Sviss - þýska - Swissmedic (Swiss Agency for Therapeutic Products)

amgen switzerland ag - darbepoetinum alfa - injektionslösung in vorgefülltem pen (sureclick) - darbepoetinum alfa 15 µg, natrii phosphates, natrii chloridum, polysorbatum 80, aqua ad iniectabilia q.s. ad solutionem pro 0.375 ml corresp., darbepoetinum alfa 40 µg/ml. - stimulierung der erythropoese - biotechnologika